文献速递乳腺癌放疗

乳房切除术后乳腺癌大分割与常规分割放疗比较:荟萃分析与系统综述

Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review.
PubMed 文献 · Radiat Oncol · 2020-01-17

结果显示两组在总生存、无病生存、局部区域复发、远处转移及各项急慢性毒性上均无显著差异。作者认为大分割放疗在乳房切除术后乳腺癌中疗效与毒性不劣于常规分割,但需更多大型随机试验证实。

要点

  • 大分割与常规分割放疗在乳房切除术后乳腺癌的疗效无显著差异。
  • 两组急性皮肤、急性肺、晚期皮肤、淋巴水肿、肩部活动受限及晚期心脏毒性均无显著差异。
  • 结论需更多大型随机临床试验进一步确认。

核心结论

  • 与常规分割放疗相比,大分割放疗在乳房切除术后乳腺癌中的疗效和毒性无显著差异。
  • 需更多大型随机临床试验进一步确认该结论。

研究设计与样本

  • 荟萃分析与系统综述,检索PubMed、EMbase、Cochrane Library、Google Scholar、万方和CNKI数据库。
  • 主要终点为总生存(OS),次要终点包括无病生存(DFS)、局部区域复发(LRR)、远处转移(DM)及多项急慢性毒性。

主要发现

  • OS无显著差异(OR=1.08,95%CI=0.87~1.33,P=0.49)。
  • DFS无显著差异(OR=1.13,95%CI=0.91~1.40,P=0.28)。
  • LRR无显著差异(OR=1.01,95%CI=0.76~1.33,P=0.96)。
  • DM无显著差异(OR=1.16,95%CI=0.85~1.58,P=0.34)。
  • 急性皮肤毒性、急性肺毒性、晚期皮肤毒性、淋巴水肿、肩部活动受限及晚期心脏相关毒性均无显著差异。

关键数值与推荐

  • 急性皮肤毒性OR=0.94,95%CI=0.67~1.32,P=0.72。
  • 急性肺毒性OR=0.94,95%CI=0.74~1.20,P=0.62。
  • 晚期皮肤毒性OR=0.98,95%CI=0.75~1.27,P=0.88。
  • 淋巴水肿OR=0.99,95%CI=0.77~1.28,P=0.94。
  • 肩部活动受限OR=0.75,95%CI=0.43~1.31,P=0.31;晚期心脏相关毒性OR=1.17,95%CI=0.82~1.65,P=0.39。

临床怎么用

  • 乳房切除术后乳腺癌患者可考虑大分割放疗,其疗效与毒性在纳入研究中与常规分割放疗无显著差异。
  • 临床决策仍需结合患者具体情况,并关注后续大型随机试验证据。

局限性

  • 结论需更多大型随机临床试验进一步确认。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To compare the efficacy and toxicity of hypofractionated radiotherapy versus conventional fractionated radiotherapy in postmastectomy breast cancer using meta-analysis. METHODS: The PubMed, EMbase, Cochrane Library, Google Scholar, Wan Fang and CNKI databases were searched to identify controlled clinical trials comparing hypofractionated radiotherapy versus conventional fractionated radiotherapy in postmastectomy breast cancer. Overall survival (OS) was the primary endpoint, and disease-free survival (DFS), locoregional recurrence (LRR), distant metastasis (DM), acute skin toxicity, acute lung toxicity, late skin toxicity, lymphedema,, shoulder restriction, and late cardiac related toxicity were the secondary endpoints. RESULTS: Twenty-five controlled clinical trials involving 3871 postmastectomy breast cancer patients were included in this meta-analysis according to the selection criteria. The meta-analysis revealed that there were no significant differences in OS (OR = 1.08, 95% CI = 0.87~1.33, P = 0.49), DFS (OR = 1.13, 95% CI = 0.91~1.40, P = 0.28), LRR (OR = 1.01, 95% CI = 0.76~1.33, P = 0.96), DM (OR = 1.16, 95% CI = 0.85~1.58, P = 0.34), acute skin toxicity (OR = 0.94, 95% CI = 0.67~1.32, P = 0.72), acute lung toxicity (OR = 0.94, 95% CI = 0.74~1.20, P = 0.62), late skin toxicity (OR = 0.98, 95% CI = 0.75~1.27, P = 0.88), lymphedema (OR = 0.99, 95% CI = 0.77~1.28, P = 0.94), shoulder restriction (OR = 0.75, 95% CI = 0.43~1.31, P = 0.31), or late cardiac related toxicity (OR = 1.17, 95% CI = 0.82~1.65, P = 0.39) between the two groups. CONCLUSIONS: The results of this study show that compared to conventional fractionated radiotherapy, hypofractionated radiotherapy is not significantly different with respect to efficacy or toxicity in postmastectomy breast cancer. Additional large randomized clinical trials are needed to further confirm this conclusion.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Liu L, Yang Y, Guo Q, et al. Comparing hypofractionated to conventional fractionated radiotherapy in postmastectomy breast cancer: a meta-analysis and systematic review. Radiat Oncol. 2020. PMID: 31952507. doi:10.1186/s13014-020-1463-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。